Clinical Study on Qinghua Formula No.1(清化方1号)in Treatment of Metabolic Associated Fatty Liver Disease of Internal Stagnation of Turbidity-dampness Type

WANG Dehe; WANG Yiqun; ZHOU Pan; HOU Luming; ZHANG Wei; LI Ying

doi:10.16295/j.cnki.0257-358x.2023.10.007

Abstract：Objective:To observe the clinical efficacy of Qinghua Formula No.1(清化方 1号)in the treat-ment of metabolic associated fatty liver disease(MAFLD)of internal stagnation of turbidity-dampness type.Methods:Total 90 patients with MAFLD were divided into the control group and the observation group with random number table method,with 45 cases in each group respectively.The observation group was treated with Qinghua Formula No.1 combined with diet and exercise basic therapy,while the control group was treated with basic therapy.Both groups were treated for 12 weeks.The controlled attenuation parameter(CAP)value and liver B-ultrasonography were compared between the two groups before and after treatment to evaluate the clinical efficacy.Serum levels of alanine aminotransferase(ALT),aspartate aminotransferase(AST),glutamyl transpeptidase(GGT),total cholesterol(TC),triglyceride(TG),low density lipoprotein(LDL)and uric acid(UA),and changes of fasting blood glucose(FPG),fasting insulin(FINS),insulin resistance index(HOMA-IR),body mass index(BMI)and waist-to-hip ratio(WHR)between the two groups before and after treatment were compared.Results:After treatment,CAP decreased significantly in both groups,and the observation group was lower than the control group(P＜0.05),but the comparison of the efficacy of CAP as an evaluation index showed no statistical significance between the two groups(P＞0.05),and the comparison of the efficacy of B-ultrasound as an evaluation index showed no statistical significance between the two groups(P＞0.05).After treatment,there were no statistically significant differences in ALT,AST and GGT between and within two groups(P＞0.05).After treatment,TG,FINS and HOMA-IR levels in two groups were lower than those before treatment,and the observation group was lower than the control group(P＜0.05).After treatment,the levels of TC,LDL,UA and FPG in the observation group were lower than those before treatment(P＜0.05),and the levels of TC,LDL and UA in the observation group were lower than those in the control group(P＜0.05).After treatment,BMI and WHR in observation group were lower than those before treatment,and BMI of the observation group was lower than that of the control group(P＜0.05).Conclusion:Qinghua Formula No.1 can improve the dyslipidemia and insulin resistance of MAFLD patients of internal stagnation of turbidity-dampness type,and help to reduce patients'body weight.